Metropolitan Life Insurance Company (MetLife)’s Relmada Therapeutics RLMD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,651	Closed	-$61.1K	–	2364
2022 Q3	$61.1K	Hold	1,651	–	–	﹤0.01%	1322
2022 Q2	$31.4K	Hold	1,651	–	–	﹤0.01%	1790
2022 Q1	$44.6K	Sell	1,651 -3,013	-65%	-$62.3K	﹤0.01%	1663
2021 Q4	$105K	Hold	4,664	–	–	﹤0.01%	2448
2021 Q3	$122K	Hold	4,664	–	–	﹤0.01%	2413
2021 Q2	$149K	Hold	4,664	–	–	﹤0.01%	2367
2021 Q1	$164K	Hold	4,664	–	–	﹤0.01%	2156
2020 Q4	$150K	Hold	4,664	–	–	﹤0.01%	2134
2020 Q3	$175K	Hold	4,664	–	–	﹤0.01%	1852
2020 Q2	$209K	Buy	+4,664	New	+$197K	﹤0.01%	1764

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RLMD Position: Q4 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 1,651 shares — an estimated $61.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $209K in Q2 2020. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,651 Relmada Therapeutics shares in Q4 2022, an estimated $61.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Relmada Therapeutics position peaked at $209K in Q2 2020.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.